Pharmaceuticals Global News & Press Release Distribution

Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial

Approximately 5% of Americans suffer from Major Depressive Disorder (MDD),[1] which is commonly associated with "foggy thinking" but a new clinical trial raises hope that once-a-day oral drug Xanamem® may assist where treatment by anti-depressant medication alone is inadequate SYDNEY, Dec. 14, 2...

2022-12-14 21:52 2899

E-Home Household Services Holdings Limited's subsidiary Zhong Run Launches Cloud Pharmacy Service to Address New Situation of Epidemic Prevention and Control

FUZHOU, China, Dec. 14, 2022 /PRNewswire/ -- E-Home Household Service Holdings Limited (Nasdaq: EJH) (the "Company" or "E-Home"), a provider of integrated household services inChina, today announced that the Company's subsidiary Zhongrun (Fujian) Pharmaceutical Co., Ltd. ("Zhongrun") plan to expa...

2022-12-14 21:30 3374

Hovione and GEA announce a strategic collaboration to advance Continuous Tableting

LISBON, Portugal, Dec. 14, 2022 /PRNewswire/ -- Hovione and GEA today announced a strategic collaboration to advance Continuous Tableting. This partnership stemmed from a successful customer-supplier relationship spanning several years. It combines GEA´s engineering expertise with Hovione´s devel...

2022-12-14 21:00 2654

Hovione and GEA announce a strategic collaboration to advance Continuous Tableting

Sirnaomics Executive Director Dr. Xiaochang Dai to Deliver Keynote Speech at BIOHK2022

GERMANTOWN, Md. and HONG KONG, Dec. 13, 2022 /PRNewswire/ -- Sirnaomics Ltd. ( the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in the discovery and development of advanced therapeutics centered around the messenger RNA ("mRNA"), announced today that its Ex...

2022-12-14 01:40 2857

Biosion Announces Research Collaboration with ImmunoGen to Create Novel Antibody-Drug Conjugates

Collaboration to explore potential of creating next-generation antibody-drug conjugateswith Biosion's SynTracer® internalization platform and ImmunoGen's proprietary linker-payload technology NEWARK, Del., Dec. 13, 2022 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global R&D biotechnology comp...

2022-12-13 18:00 2627

Live from ASH 2022 | Ascentage Pharma Presents Latest Data of APG-2575, Including Encouraging Results of the Combination with BTKi in Patients with R/R CLL/SLL

SUZHOU, China and ROCKVILLE, Md. , Dec. 13, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has released preliminary results from a ...

2022-12-13 17:39 2766

CARsgen Presents Data from China Pivotal Phase II Trial of BCMA CAR T Zevor-cel (CT053) at 2022 ASH Annual Meeting

SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thatat the 2022 American Society of Hematology (the "ASH") Annual Mee...

2022-12-12 21:50 3238

PharmAbcine Announces Collaboration Agreement with MSD to Evaluate Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDA® (pembrolizumab)

DAEJEON, South Korea, Dec. 12, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company has entered into a clinical collaboration agreement with MSD (Merck & Co...

2022-12-12 21:00 3133

Asieris'Bladder Cancer Diagnostic Drug Hexvix® Completed Dosing of First Patient in Real-World Clinical Study

SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that Hexvix®, a drug used for bladder c...

2022-12-12 20:59 2442

Asieris Enrolled First Patient for its Phase II Clinical Study of Oral APL-1202 in Combination with Tislelizumab, a PD-1 inhibitor, as Neoadjuvant Therapy for Muscle Invasive Bladder Cancer

SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the first patient enrolled in phas...

2022-12-12 17:47 2347

SK Biopharmaceuticals' Partner Angelini Pharma Launches Cenobamate in France

Cenobamate (ONTOZRY®), for the treatment of uncontrolled focal-onset seizures in adults, is now available in 5 major European countries –Germany, the UK, Italy, Spain, France – and 10 other key markets PANGYO, South Korea, Dec. 8, 2022 /PRNewswire/ -- SK Biopharmaceuticals, an innovative global ...

2022-12-09 06:30 3324

LISCure's Phase 2 Drug Candidate Granted Orphan Drug Designation (ODD) from US FDA

First Orphan Drug Designation (ODD) in the field of microbiome-based treatment for metabolic diseases SEOUL, South Korea, Dec. 8, 2022 /PRNewswire/ -- LB-P8, a novel drug being developed by LISCure Biosciences, Inc. (LISCure) as a treatment for Primary Sclerosing Cholangitis (PSC), has been desi...

2022-12-08 22:00 2875

Createrna Announces Positive Top-Line Results from Phase 1 Clinical Trials of QR052107B Tablet in Healthy Volunteers

* QR052107B Tablet was safe and well tolerated in healthy volunteers across all tested doses, with no taste related adverse event at the anticipated therapeutic doses * Createrna initiated a clinical Phase 2 trial to study QR052107B Tablet at once-a-day (QD) dose in the treatment of refract...

2022-12-08 14:29 2889

Akeso Inc. Announces Collaboration and License Agreement for Up to US$5 Billion with Summit Therapeutics to Accelerate Global Development and Commercialization of its Breakthrough Bispecific Antibody, Ivonescimab (PD-1/VEGF)

* Akeso Inc. to out-license to Summit Therapeutics exclusive rights to ivonescimab (PD-1/VEGF) for the development and commercialization inthe United States, Canada, Europe, and Japan. Akeso Inc. will retain development and commercialization rights for the rest of the world includingChina. * ...

2022-12-06 21:01 3818

Daewoong Pharmaceutical announces success in developing a new antidiabetic medication and its aims to enter the market in over 50 countries by 2030

* Delivers new drug for two consecutive years by obtaining product license on "Envlo", Korea's 36th new drug from the Ministry of Food and Drug Safety * Plans to enter the type 2 diabetes global market worth $71.4 billion * Provides new and broad treatment options for patients with insufficie...

2022-12-06 20:00 2434

Meihua International Medical Technologies Co., Ltd. Appoints New CEO, CFO and Directors

YANGZHOU, China, Dec. 5, 2022 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries inChina, today announced the appointments...

2022-12-05 22:33 3018

China Pharma Holdings, Inc. Announced the Acquisition of Dry Eye Disease Therapeutic Device Project

HAIKOU, China, Dec. 5, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced the Acquisition of Dry Eye Disease...

2022-12-05 21:00 3593

Program CD47, provided the CMC service by GenScript ProBio to InnobationBio, will further be advanced by the joint venture between Liminatus Pharma LLC and Iris Acquisition Corp

NEW YORK and LONDON, Dec. 5, 2022 /PRNewswire/ -- Recently, Liminatus Pharma LLC ("Liminatus"), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies and Iris Acquisition Corp ("Iris") (Nasdaq: IRAA), a publicly traded special purpose acquisition company ...

2022-12-05 20:00 2234

The First IBCC Unveiled in Hainan

SHANGHAI, Dec. 5, 2022 /PRNewswire/ -- The first Integrated Bladder Cancer Center (IBCC) inHainan Province was inaugurated in Hainan General Hospital at the Hainan Provincial Urology Annual Meeting. A patient-centered facility, the IBCC serves to improve inpatient experiences as well as medical s...

2022-12-05 15:55 2139

China Pharma Announces Receipt of Noncompliance Notice from NYSE American

HAIKOU, China, Dec. 2, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that onDecember 1, 2022, received a notification (the "Deficiency Letter") from the NYSE American LLC (the "NY...

2022-12-03 05:10 4618